Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

Optimer will host a conference call tomorrow at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss this announcement. To participate in the conference call, please dial (877) 280-7280 from the U.S., or (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Conference Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call. Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. 

About DIFICID™ (Fidaxomicin)

DIFICID™ (fidaxomicin) is a new antibiotic with a novel mechanism of action, which inhibits the bacterial enzyme RNA polymerase, resulting in the rapid killing of C. difficile. The narrow-spectrum profile of DIFICID eradicates C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics used to treat CDI, metronidazole and vancomycin, have been shown to disrupt the gut flora. DIFICID facilitates the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence rates. In two Phase 3 trials for the treatment of CDI, DIFICID was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  DIFICID also demonstrated statistically significant reduction in recurrences and an increase in global cure rate, defined as cure without recurrence. Importantly, DIFICID reduced the risk of recurrence by 47% compared to vancomycin. The New England Journal of Medicine has published results from the first Phase 3 trial in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," which
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- SeraCare Life Sciences, a leading partner to global ... AACC Annual Meeting today that it has signed ... biotechnology company that develops, markets and sells preanalytic ... ViveST™ allow sample collection, transport and storage in ... of the agreement, the two firms will jointly ...
(Date:7/27/2015)... July 27, 2015  The fairness of the proposed ... St. Jude Medical ("St. Jude") is the subject of ... shareholder rights law firm.  The investigation is focusing on ... law by the Board of Directors of THOR for ... July 22, 2015, the Company announced it had reached a ...
(Date:7/27/2015)... , July 20, 2015 ... has announced the addition of the "Cardiometabolic ... Afrezza,s discounted pricing is in line ... is critical to the product,s commercial appeal. However, ... prevent Afrezza from gaining a sizeable share of ...
Breaking Medicine Technology:SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 2SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 3WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3
... Motion Therapeutics, Inc. http://www.motiontherapeutics.com , the leading provider ... today announced that researchers at Samuel Merritt University and ... to study the effects of wearing a strategically weighted ... MS. This grant comes after the ...
... Argon Medical Devices, Inc. announced today that it ... LP ("Rex Medical") for exclusive global rights to market and ... device used in the prevention of Pulmonary Embolism (PE). ... to our product portfolio. This proven technology has rapidly become ...
Cached Medicine Technology:The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 3
(Date:7/28/2015)... ... July 28, 2015 , ... ... that Schneider Electric has completed its upgrade and expansion of its ... with more than 170,000 employees in 134 countries supplying a wide range of ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... biologics and biologic-device combination products for the treatment of bone disorders and conditions ... Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". The ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new Taiwanese study suggests ... are in the general population. Surviving Mesothelioma has just posted an article detailing ... at Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the health ...
(Date:7/28/2015)... MA (PRWEB) , ... July 28, 2015 , ... Women ... cancer. One reason is that cancer, heart attack, and stroke are treatable, but there ... thing individuals can do is to take part in a clinical trial, reports the ...
(Date:7/28/2015)... ... July 28, 2015 , ... Every summer, the public is reminded ... caution when lighting fireworks in their own neighborhoods. Unfortunately, according to a recent report ... 3, 2015 USA Today article " Eye Injuries Caused by Fireworks Doubled in Last ...
Breaking Medicine News(10 mins):Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3
... (Jan. 17, 2008) Twenty research projects have been ... at the Argonne Leadership Computing Facility (ALCF) at Argonne ... competitively selected group of 55 scientific projects announced Thursday ... awards are made through the 2008 Innovative and Novel ...
... diagnostic tool to detect surface cancers quickly and ... calculate body composition has been developed by a ... from QUTs School of Physical and Chemical Sciences ... spectroscopy to diagnose cervical and skin cancers. , ...
... stroke and even death, study finds , , FRIDAY, ... to aspirin are four times more likely to suffer a ... says. , People who are aspirin-resistant have platelets -- the ... in the same way as platelets in people who respond ...
... Jan. 18 Cardiac Science,Corporation (Nasdaq: ... cardiac diagnosis,resuscitation, rehabilitation, and informatics products, announced ... its first responder units with,425 Powerheart(R) G3 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO ), "Like first ...
... Farm Safety 4 Just Kids Founder, Adams, Reaches Finals of 6th Annual Volvo ... Celebrity Judges Will Select and Unveil Top Four Winners March 19 at Volvo,for life ... ... Life, IRVINE, Calif., Jan. 18 For the past ...
... Jan. 18 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: ... reduction in its,overall headcount affecting approximately 115 people ... U.S. subsidiaries, including members,of its management team., ... undertaken by the,Company as part of its strategic ...
Cached Medicine News:Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 2Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 3Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 4Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 5Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 6Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 7Health News:Cardiac Science Completes Deployment of AEDs With Los Angeles County Fire Department 2Health News:Cardiac Science Completes Deployment of AEDs With Los Angeles County Fire Department 3Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 2Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 3Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 4Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 5Health News:QLT reduces workforce as first step in its strategic restructure 2Health News:QLT reduces workforce as first step in its strategic restructure 3
... care challenge., ,The S/5 Critical Care Monitor ... solution for the varying needs of critical care. ... of parameter module options, display and mounting options, ... optimize the bedside set-up to help meet your ...
... connectivity, ,The wireless functionality is an ... that makes it possible to connect S/5 ... S/5 Central Station via Wireless LAN technology., ... of providing continuous centralized surveillance within the ...
... day surgery and post anesthesia care in one ... is a high performance monitor designed for the ... and induction rooms. It offers the flexibility of ... advanced airway gas monitoring. When paired with the ...
Anesthetists Precordial Kit incudes one set of 4 chromed plated chest pieces, a reusable monoscope of your choice, and 20 precordial adhesive discs....
Medicine Products: